Ads
related to: hcv polymerase inhibitors for breast cancer therapy- Treatment Information
Read About This Treatment Option.
Learn How This Option May Help.
- Early Breast Cancer
Find Condition Information.
Understand eBC.
- Patient FAQ Answers
View Frequently Asked Questions.
Get Answers To Common Questions.
- Clinical Data
See The Data For This Option.
eBC Clinical Trial Information.
- Managing Day To Day
Info For Day To Day Support.
Find Support Organizations.
- Patient Resources
Access Helpful Patient Materials.
Download Resources Today.
- Treatment Information
Search results
Results From The WOW.Com Content Network
Cure rates are 94% to 99% in people infected with genotype 1 (46% of HCV cases). [15] It has also been evaluated for the treatment of infection with other hepatitis C genotypes, and has shown promising results in genotypes 3 and 4 (making up 30% and less than 22% of HCV cases respectively). [9] [6] [16] [15]
Alpelisib is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
It contains sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor; velpatasvir, an HCV NS5A inhibitor; and voxilaprevir an HCV NS3/4A protease inhibitor. [ 2 ] [ 5 ] The most common adverse reactions include headache, fatigue, diarrhea, and nausea.
Refractory metastatic melanoma, childhood acute lymphoblastic leukaemia, chronic myeloid leukaemia in blast crises, neuroblastoma, non-small cell lung cancer and breast cancer. Myelosuppression, neurotoxicity and paralytic ileus. Vinflunine: IV: As above. Bladder cancer: As per vinblastine. Vinorelbine: IV: As above. Breast cancer and non-small ...
In the United States, it is indicated for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in ...
In the European Union it was approved in July 2016, for the treatment of chronic hepatitis C virus infection in adults. [7] The safety and efficacy of sofosbuvir/velpatasvir for a 12-week treatment was evaluated in three Phase III clinical trials of 1,558 subjects without cirrhosis or with compensated cirrhosis (mild cirrhosis). [13]
Ads
related to: hcv polymerase inhibitors for breast cancer therapy